A Phase 3 interventional study of Propofol-based total intravenous anesthesia and Sevoflurane intravenous anesthesia in Esophageal Cancer, sponsored by The Cleveland Clinic. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by The Cleveland Clinic · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.
Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 14th largest by planned enrollment of the 394 interventional ones that give a count, is one of 26 that started in 2020, is one of 62 in phase 3, reaches primary completion later than 134 of the 237 other live ones, and was the 201st registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Sanofi · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
502 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 189 · Phase 3 69 · Phase 4 8
First in 1995; this study’s year is marked. 26 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,614 is above the median of 58 across 1,347 interventional studies indexed under Esophageal Neoplasms.
Median enrollment 80 across the 394 interventional studies, 300 across the 108 observational. Of the 120 that completed or were terminated, 7 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 502 have an industry lead sponsor. The 10 most frequent:
The Cleveland Clinic is the lead sponsor of 832 studies on the registry; 119 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 73 (81%) have results posted.
The Cleveland Clinic has 2 studies filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
61 of the studies in Esophageal Neoplasms with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04513808Phase 3The Cleveland ClinicTotal Intravenous Anesthesia and Recurrence Free Survival | 2026-12 |
| NCT04415853Phase 3Sunshine Lake Pharma Co., Ltd.Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | 2027-08 |
| NCT07303231Phase 3Fujian Medical University Union HospitalThe Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy | 2027-08-01 |
| NCT05252078Jiangxi Provincial Cancer HospitalAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | 2026-11 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
Add all 61 to your calendar (.ics) → With an account.
Among the 502 studies in Esophageal Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.
The investigators will test the primary hypothesis that recurrence-free survival after esophageal cancer surgery is longer in patients randomized to propofol-based total intravenous anesthesia than to volatile sevoflurane anesthesia.
The investigators will test the secondary hypotheses that propofol-based total intravenous anesthesia: 1) speeds discharge from the ICU; 2) speeds discharge from the hospital; and, 3) improves the quality of recovery, as assessed by QoR-15 on postoperative day 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Propofol-based total intravenous anesthesia. A target-controlled infusion will be set to 2-4 µg/ml plasma concentrations, and varied as clinical necessary.
Drug: Propofol-based total intravenous anesthesia
Anesthesia will be maintained with sevoflurane, typically at an end-tidal concentration of 0.6-1.0 MAC, but adjusted as clinically necessary
Drug: Sevoflurane intravenous anesthesia
Propofol-based total intravenous anesthesia, titrated to clinical need.
Also known as: Propofol
Sevoflurane intravenous anesthesia, titrated to clinical need.
Also known as: Sevoflurane
Recurrence-free survival
Patients who did not experience cancer recurrence and/or death.
Time frame: 4 years
ICU duration
Postoperative time in ICU during initial admission.
Time frame: From ICU admission until the date of ICU discharge or date of death from any cause, whichever came first, assessed up to 100 months
Hospital duration
Postoperative time spent in hospital during initial admission.
Time frame: Up to 100 months
QoR-15
Quality of Recovery 15 score on postoperative day 2.
Time frame: 2 days
Plan to share: Yes — Data will be shared collaboratively with appropriate approvals and contracts.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: 2 years after publication of the main paper.
Access criteria: Contact investigators.
No publications or documents are linked to this record.
Started Aug 2020 (actual). Primary completion is estimated for Dec 2026, 76 months after the start.
Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's planned 76 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Propofol · Sevoflurane